Allovir Terminates Material Definitive Agreement
Ticker: KLRS · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $5,700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, corporate-action
TL;DR
Allovir just terminated a key agreement with ViraCyte. Big changes ahead?
AI Summary
Allovir, Inc. announced on June 5, 2024, the termination of its Material Definitive Agreement with ViraCyte, Inc. The company, formerly known as ViraCyte, Inc., is incorporated in Delaware and headquartered in Waltham, Massachusetts.
Why It Matters
The termination of a material definitive agreement can signal significant changes in a company's strategic partnerships or operational structure, potentially impacting its future business and financial performance.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding future operations and financial stability.
Key Players & Entities
- Allovir, Inc. (company) — Registrant
- ViraCyte, Inc. (company) — Former company name and party to terminated agreement
- June 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Waltham, Massachusetts (location) — Principal executive offices
FAQ
What was the specific nature of the Material Definitive Agreement between Allovir, Inc. and ViraCyte, Inc. that was terminated?
The filing states that the agreement was a 'Material Definitive Agreement' but does not provide specific details about its nature or terms.
What is the reason for the termination of the Material Definitive Agreement?
The filing does not disclose the specific reasons for the termination of the Material Definitive Agreement.
When did the termination of the Material Definitive Agreement become effective?
The earliest event reported is June 5, 2024, which is the date of the report concerning the termination.
Does the termination of this agreement have any immediate financial implications for Allovir, Inc. that are detailed in this filing?
This filing does not detail immediate financial implications; it primarily serves as notification of the agreement's termination.
Is there any ongoing relationship or dispute between Allovir, Inc. and ViraCyte, Inc. following this termination?
The filing does not provide information regarding any ongoing relationships or disputes subsequent to the termination.
Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-11 17:10:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALVR Nasdaq Glo
- $5,700,000 — on fee (the "Lease Termination Fee") of $5,700,000. The Lease Termination Fee shall be due
Filing Documents
- d830314d8k.htm (8-K) — 26KB
- d830314dex101.htm (EX-10.1) — 37KB
- 0001193125-24-159226.txt ( ) — 193KB
- alvr-20240605.xsd (EX-101.SCH) — 3KB
- alvr-20240605_lab.xml (EX-101.LAB) — 18KB
- alvr-20240605_pre.xml (EX-101.PRE) — 11KB
- d830314d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Sublease Termination Agreement, dated June 5, 2024, by and between AlloVir, Inc. and AMAG Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AlloVir, Inc. Date: June 11, 2024 By: /s/ Edward Miller Name: Edward Miller Title: General Counsel